UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class: |
| Trading Symbol(s) |
| Name of Each Exchange on which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)Resignation of Andrew Powell as Director
On March 14, 2024, Andrew Powell, a member of the board of directors (the “Board”) of Aclaris Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “Annual Meeting”). Mr. Powell’s resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Decision of Bryan Reasons Not to Stand for Re-election to the Board
Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting. Mr. Reasons’ refusal to stand for re-election was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ACLARIS THERAPEUTICS, INC. | ||
By: | /s/ Kevin Balthaser | |
Date: March 19, 2024 | Kevin Balthaser | |
Chief Financial Officer |
3
Document and Entity Information |
Mar. 14, 2024 |
|---|---|
| Document and Entity Information | |
| Document Type | 8-K |
| Document Period End Date | Mar. 14, 2024 |
| Entity File Number | 001-37581 |
| Entity Registrant Name | Aclaris Therapeutics, Inc. |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 46-0571712 |
| Entity Address, Address Line One | 701 Lee Road |
| Entity Address, Adress Line Two | Suite 103 |
| Entity Address, City or Town | Wayne |
| Entity Address, State or Province | PA |
| Entity Address, Postal Zip Code | 19087 |
| City Area Code | 484 |
| Local Phone Number | 324-7933 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.00001 par value |
| Trading Symbol | ACRS |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Entity Central Index Key | 0001557746 |
| Amendment Flag | false |